ADVL1721: A Non-Randomized, Open Label, Multi-Center, Phase 1/11 Study of P13K Inhibitor Copanlisib in Pediatric Patients with Relapsed/Refactory Solid Tumors or Lymphoma

Grant

Total Award Amount

  • 52467.00
  • Direct Costs

  • 40359.00
  • Sponsor Award Id

  • Contributor

  • axavier1   Investigator  
  • eejohnst   Investigator  
  • kifowler   Investigator  
  • kmetrock   Investigator  
  • mkutny   Investigator  
  • Elizabeth Alva   Investigator  
  • Gregory Friedman M.D.   Principal Investigator  
  • Jamie Aye   Investigator